{"nctId":"NCT01926197","briefTitle":"Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer","startDateStruct":{"date":"2013-08-14","type":"ACTUAL"},"conditions":["Pancreatic Cancer"],"count":27,"armGroups":[{"label":"Modified FOLFIRINOX","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oxaliplatin","Drug: Irinotecan","Drug: Leucovorin","Drug: 5FU"]},{"label":"Modified FOLFIRINOX plus Stereotactic Body Radiotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Oxaliplatin","Drug: Irinotecan","Drug: Leucovorin","Drug: 5FU","Radiation: Stereotactic Body Radiotherapy (SBRT)"]}],"interventions":[{"name":"Oxaliplatin","otherNames":["Eloxatin"]},{"name":"Irinotecan","otherNames":["Camptosar","Camptothecin-11 (CPT-11)","Campto","Onivyde"]},{"name":"Leucovorin","otherNames":["Folinic acid","Wellcovorin","Citrovorum Factor"]},{"name":"5FU","otherNames":["5-fluorouracil","Tolak","Fluoroplex","Efudex","Carac","Adrucil"]},{"name":"Stereotactic Body Radiotherapy (SBRT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA\n\n* Histologically-confirmed adenocarcinoma of the pancreas\n* Determined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or gastrointestinal oncology Tumor Board.\n* Stable or better disease on re-staging scans\n* Typically, tumors \\< 8.0 cm in greatest axial dimension but final determination of eligibility based upon radiation normal tissue constraints\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2\n* Leukocytes (white blood cells, WBC) ≥ 3,000/mL\n* Absolute neutrophil count (ANC) ≥ 1,500/mL\n* Platelets ≥ 50,000/mL\n* Total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 X institutional ULN\n* Creatinine within normal institutional limits\n* Ability to understand and the willingness to sign an informed consent form\n* Life expectancy \\> 6 months\n\nEXCLUSION CRITERIA\n\n* Metastatic disease\n* Prior radiotherapy to the upper abdomen/liver.\n* Prior chemotherapy for pancreatic cancer, other than up to 4 cycles of modified FOLFIRINOX.\n* Age \\< 18 years\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection (or infections requiring systemic antibiotic treatment)\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness/social situations that would limit compliance with study requirements.\n* Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy without evidence of disease for \\> 5 years will be allowed to enter the trial.\n* Pregnant or lactating\n* Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) for duration of the study\n* Women who are not post-menopausal (as defined in Appendix III) and have a positive urine or serum pregnancy test or refuse to take a pregnancy test\n* Male subjects who are unwilling or unable to use effective contraception for duration of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) means the period of time that a participant remains alive without tumor progression either locally or at a distant site in the body (metastasis). The effect of the study treatments was assessed as the median PFS of participants in the treatment groups. The outcome is reported as the median PFS with standard deviation.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"6.6"},{"groupId":"OG001","value":"8.4","spread":"9.5"}]}]}]},{"type":"SECONDARY","title":"Local Progression-free Survival (Local PFS)","description":"Local progression-free survival (PFS) means the period of time that a participant remains alive without recurrence or advancement of the disease at the baseline sites of the tumor (local progression). The effect of the study treatments was assessed as the median local PFS of participants in the treatment groups. The outcome is reported as the median local PFS with standard deviation.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"6.6"},{"groupId":"OG001","value":"8.4","spread":"10.5"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) at 1 Year","description":"Progression-free survival (PFS) means the period of time that a participant remains alive without tumor progression either locally or at a distant site in the body (metastasis). The effect of the study treatments was assessed as the number of participants in each treatment group that remained alive without tumor progression, at 1 year after treatment.\n\nThe outcome is reported as a number without dispersion.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Metastasis-free Survival (MFS)","description":"Metastasis-free survival (MFS) means the period of time that a participant remains alive without the appearance of new tumor lesions a distant site in the body (metastasis). The effect of the study treatments was assessed as the median MFS of participants in the treatment groups. The outcome is reported as the median PFS with standard deviation.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":"6.4"},{"groupId":"OG001","value":"10.8","spread":"16.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The effect of the study treatments was assessed as the length of time participants in each treatment group that remained alive. The outcome is reported as the median OS with standard deviation.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":"6.4"},{"groupId":"OG001","value":"13.4","spread":"16.6"}]}]}]},{"type":"SECONDARY","title":"Grade 2 or Greater Gastrointestinal (GI) Toxicity","description":"Toxicity means an adverse event related to the study treatment. Toxicity was assessed between treatment groups as the number of treatment-related , ≥ grade 2 events of gastritis, fistula, enteritis, or ulcer; plus any other Grade 3 to 5 gastrointestinal (GI) toxicity. The outcome is reported as the number of defined adverse events by preferred term for each treatment group, occurring within 3 months of the start of treatment. These adverse events by definition are all within the Common Terminology Criteria for Adverse Events (CTCAE) version 4.01 Gastrointestinal Body System. The outcome is reported as numbers without dispersion.\n\nAll-cause Mortality mFFX 7 SBRT 8","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":12},"commonTop":["Fatigue","Anemia","Platelet count decreased","Nausea","Pain, abdominal"]}}}